Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ELOVL6 activity attenuation induces mutant KRAS degradation.

Nature chemical biology - 1 Mar 2026

Hu Xiyue, Atwal Ranjit Singh, Xiao Sophie, Ahmed Sharif U, Wang Zongjie, Zhao Chenlin, Wang Hansen, Kelley Shana O

Abstract excerpt

KRAS is one of the most frequently mutated oncogenes in cancer. Targeting mutant KRAS directly has been challenging because of minor structural changes caused by mutations. Despite recent success in targeting KRAS-G12C, targeted therapy for another hotspot mutant, KRAS-G12V, has not been described. We used CRISPR-Cas9 genome-wide knockout screens to identify genes that specifically modulate mutant KRAS harboring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Acetyltransferases
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acid Elongases

Share to KRAS gene

Share to Mutation

Share to Proteolysis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 40954224
DOI: 10.1038/s41589-025-01998-x

Genes

KRAS
ELOVL6

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ELOVL6 activity attenuation induces mutant KRAS degradation.PMID 40954224Read ↗

A comprehensive review of the family of very-long-chain fatty acid elongases: structure, function, and implications in physiology and pathologySemantic proximity Read ↗

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read ↗

ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic CancerSemantic proximity Read ↗

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.Semantic proximity Read ↗

<i>In vivo</i> AAV9-SB-CRISPR screen identifies fatty acid elongase ELOVL5 as a pro-resolving mediator in lung inflammationSemantic proximity Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Semantic proximity Read ↗

Genetic identification of the RAS proteostatic machinery and its failure to regulate oncogenic variantsSemantic proximity Read ↗

BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.Semantic proximity Read ↗

Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis.Semantic proximity Read ↗

KRAS G12C and KRAS G12D respond to lipid metabolism in an allele-specific manner.Semantic proximity Read ↗

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.